BridgeBio Pharma EBITDA Margin 2018-2024 | BBIO

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for BridgeBio Pharma (BBIO) over the last 10 years. The current EBITDA margin for BridgeBio Pharma as of June 30, 2024 is .
BridgeBio Pharma EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-06-30 $0.22B $-0.50B -230.14%
2024-03-31 $0.22B $-0.47B -216.44%
2023-12-31 $0.01B $-0.60B -6010.00%
2023-09-30 $0.01B $-0.55B -5530.00%
2023-06-30 $0.01B $-0.52B -8733.33%
2023-03-31 $0.08B $-0.46B -588.46%
2022-12-31 $0.08B $-0.51B -648.72%
2022-09-30 $0.09B $-0.54B -608.99%
2022-06-30 $0.09B $-0.56B -619.78%
2022-03-31 $0.07B $-0.58B -811.27%
2021-12-31 $0.07B $-0.57B -827.54%
2021-09-30 $0.06B $-0.53B -953.57%
2021-06-30 $0.06B $-0.51B -816.13%
2020-09-30 $0.02B $-0.43B -1931.82%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.791B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00